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Figure 1 – Abdominal X-ray of the patient showing clustered 
calciﬁcations in projection of the kidneys, more evident at 
the right side (upper arrow identiﬁes one of these clusters). 
An 8-mm right distal ureteral stone is present (lower arrow).
A 46-year-old white woman has been followed in this 
nephrology clinic since 1995 due to recurrent nephroli-
thiasis and medullary nephrocalcinosis resulting from 
renal tubular acidosis (urinary pH of 8 in the context of 
systemic normal anion gap acidosis; serum potassium at 
lower limit, and 24-hour urine with normocalciuria but 
no detectable citrate) due to Sjögren’s syndrome (SS). 
During follow-up, her adherence to alkali therapy had 
been suboptimal due to gastric intolerance to Shohl’s 
solution, potassium citrate, and sodium bicarbonate. 
As consequence, she had progression in her nephrocal-
cinosis and passed several urinary calculi (biochemical 
analysis showed them to be composed of calcium phos-
phate and calcium oxalate). Currently, she presents nor-
mal estimated GFR (MDRD, 82 mL/min/1.73 m2) and 
no significant proteinuria, despite having presented, ten 
years after the diagnosis of SS, onset of systemic lupus er-
ythematosus (SLE) with severe diffuse proliferative class 
IV lupus nephritis, treated successfully with corticoste-
roids and intravenous ciclophosphamide. Figure 1 shows 
the radiological appearance and Figure 2 depicts the ul-
trasonographic aspect of the patient’s nephrocalcinosis.
Nephrocalcinosis is characterized by the presence of 
calcium deposits in the renal parenchyma; nephrolithia-
sis represents calcification within the lumen of the col-
lecting system, ureter, and bladder1. Recent observation 
suggests that nephrocalcinosis and calcium nephrolithi-
asis are to be considered independent pathologies, and 
that nephrocalcinosis may cause calcium nephrolithiasis 
only in certain conditions2. Both types of renal calcifica-
tion may be present in patients with SS. Nephrocalcinosis 
may be classified as cortical or medullary, according to 
the anatomic area involved3. When associated with SS, it 
is typically medullary and secondary to distal renal tubu-
lar acidosis (RTA). It is believed that the renal acidifica-
tion problem seen in patients with SS is due to immune-
mediated loss of proton regulation4. In addition to RTA, 
other disorders such as hyperparathyroidism, medullary 
sponge kidney, renal papillary necrosis, renal tubercu-
losis, hyperoxaluria, milk-alkali syndrome, sarcoidosis, 
immobilization, and other conditions associated with 
hypercalcemia and hypercalciuria, may cause medullary 
nephrocalcinosis. 
Nephrocalcinosis is usually identifiable by X-ray, 
but both ultrasonography (US) and computed tomogra-
phy (CT) can detect it earlier than ordinary abdominal 
X-ray1. US is considered to be an excellent diagnostic 
method for detection and monitoring of nephrocalci-
nosis3. The finding of hyperchogenic pyramids with a 
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normally echogenic cortex is believed to be specific to 
medullary nephrocalcinosis3,5. Despite being an excellent 
diagnostic method as well, CT (usually performed with-
out radiocontrast) involves a considerable dose of radia-
tion, which may limit its use for the follow-up of patients 
with nephrocalcinosis. Indeed, CT was found to be un-
necessary for the clinical management of the patient.
Finally, the importance of investigating SS in patients 
with medullary nephrocalcinosis or nephrolithiasis as-
sociated with renal tubular acidosis, especially women, 
regardless of the presence of keratitis sicca or systemic 
symptoms, is emphasized, because it may be the first 
manifestation of the syndrome. Therapy for correction of 
acidosis is intended to control the nephrocalcinosis and 
preserve renal function6. This case corroborates that al-
though RTA is a treatable urologic condition, incomplete 
treatment can lead to progression of nephrocalcinosis.
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Figure 2 – Ultrasonographic appearance of patient’s right 
kidney showing increased echogenicity of the renal medulla 
(medullary nephrocalcinosis). Black arrow shows a hypere-
choic renal pyramid with dense posterior acoustic shadow 
(white arrow).
